EVX Ventures

EVX acts primarily as a company builder. It co-founds biotech startups directly with academic scientists, taking a founder-level role rather than acting as a passive early-stage investor. Portfolio companies like Carcell Biopharma and Carmine Therapeutics were created by EVX Ventures alongside professors from institutions such as MIT and Duke-NUS Medical School (per firm website).

The portfolio concentrates on three platform clusters: engineered red blood cells for immuno-modulation and non-viral gene delivery (Carcell, Carmine); gene therapy vectors and RNA medicines for genetic heart and liver diseases (Nuevocor, Lerna Biopharma); and novel immuno-oncology targets derived from aberrant splicing and T-cell activation mechanisms (PairX Bio, AltruBio, Hummingbird Bioscience).

Deal flow originates from deep collaborations with university laboratories, particularly Duke-NUS Medical School in Singapore and Prof. Harvey Lodish's research group at MIT. The firm builds companies around published science, often securing IP from those institutions and embedding the originating scientists as co-founders or scientific advisory board chairs.

EVX targets the full preclinical-to-early-clinical continuum. It engages at the discovery stage, builds companies through target validation, and funds programs into Phase II clinical trials. Hummingbird Bioscience's pipeline is described as advancing through Phase II, while most other portfolio companies remain preclinical or Series A stage (per firm website).

The firm operates a dual-hub structure with headquarters in Singapore (Techplace II) and a substantial presence in Shanghai, China (Pudong New District). This cross-border footprint supports integrated R&D and manufacturing capabilities — Carcell Biopharma, for example, runs teams and facilities in both locations.

There is no publicly disclosed corporate parent. EVX Ventures does describe itself as a 'global VC' and company builder operating independently. It does not list affiliation with Esco Lifesciences or any other pharmaceutical group, though its domain history and entity naming suggest a possible historical relationship that the firm itself does not confirm.

EVX's disclosed activity consists exclusively of direct company-building and investment into its incubated portfolio entities. There is no public record of the firm making fund commitments to external venture managers. The firm's capital deployment appears fully concentrated in its own incubated pipeline.